One study has found that patients with high TWIST1 expression were more likely to achieve remission following standard AML induction chemotherapy (cytarabine and daunorubicin combination therapy) than those with lower TWIST1 expression, and subsequently achieved a greater overall survival (145). The gene discussed is TWIST1; the disease is acute myeloid leukemia.